Atorvastatin administration is associated with dose-related changes in IGF bioavailability
Ram P Narayanan1, Matthew Gittins, Kirk W Siddals
1Salford Royal Hospital NHS Foundation Trust, The University of Manchester, Salford, UK. ram.narayanan@manchester.ac.uk
European Journal of Endocrinology
|January 22, 2013
Summary
High-dose atorvastatin therapy showed dose-related changes in Insulin-like Growth Factor Binding Protein 1 (IGFBP1) concentrations, suggesting a potential mechanism for statin-induced glucose intolerance. Other IGF proteins did not show significant dose-related changes.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Insulin-like Growth Factor (IGF) levels, binding proteins (IGFBPs), and high-dose statin use are associated with diabetes development.
- Atorvastatin is a commonly prescribed statin.
- Understanding the dose-response relationship of atorvastatin on IGF proteins is crucial for metabolic health.
Purpose of the Study:
- To investigate dose-related changes in IGF1, IGF2, IGFBP1, and IGFBP3 concentrations with atorvastatin therapy.
- To explore potential mechanisms linking statin use to glucose metabolism alterations.
Main Methods:
- A randomized trial involving 119 participants with type 2 diabetes.
- Participants received either 10 mg or 80 mg of atorvastatin.
- Measurements of IGF1, IGF2, IGFBP1, and IGFBP3 were taken at baseline, 6, and 12 months.
Main Results:
- Atorvastatin led to overall reductions in IGF1, IGF2, and IGFBP3 concentrations.
- No significant dose-related changes were observed for IGF1, IGF2, or IGFBP3.
- A significant dose-related decrease in IGFBP1 concentration was observed with higher atorvastatin doses (P=0.004).
Conclusions:
- Atorvastatin therapy decreases IGF1, IGF2, and IGFBP3 levels.
- A significant dose-dependent effect of atorvastatin on IGFBP1 was identified.
- These findings suggest that differential effects on IGFBP1 may contribute to statin-associated glucose intolerance.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:22Bioavailability: Influencing Factors
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:13Bioavailability: Overview
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...